Leukocytoclastic Vasculitis Associated with Bortezomib Therapy

Yashwanth, Thiagarajan Raj; Vairakkani, R; Srinivasaprasad, Nagalakshmi Dhanapal; Sujith, S; Thirumalvalavan, K; Fernando, Mervin Edwin

doi:10.4103/1319-2442.301178

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion2

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Excessive secretion of inflammatory mediators, i.e., interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), is possibly responsible for bortezomib-induced vasculitis. Administration of oral corticosteroids is effective in healing the vasculitis [ 6 , 7 ]. In our case, the patient was managed by reducing the dose of bortezomib.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bortezomib-Induced Superficial Vasculitis in a Kidney Transplant Recipient: A Rare Case

Balwani,

Pasari,

Gurjar

et al. 2024

Cureus

View full text Add to dashboard Cite

Bortezomib is a frequently administered immunosuppressive agent in kidney transplantation. A 30-year-old male kidney transplant recipient developed an atypical reaction on the left hand in terms of spider-like extensions, indicating erythematous inflammation along the superficial veins after bortezomib intravenous administration. The inflammation spontaneously resolved after three weeks with a bortezomib dose reduction. Nephrologists must be familiar with the potential cutaneous bortezomib-induced adverse effects.

show abstract

Section: Discussionmentioning

confidence: 99%

“…With bortezomib, adverse events ranging from skin rash to thrombocytopenia, leukopenia, and neutropenia are reported [5]. Bortezomib-induced skin issues, including cutaneous vasculitis, are common but poorly understood [6,7]. In bortezomib clinical trials, vasculitis and rashes are reported in 8-18% of patients.…”

Section: Discussionmentioning

confidence: 99%